CytomX Therapeutics (CTMX) Deferred Taxes (2015 - 2017)

CytomX Therapeutics has reported Deferred Taxes for 3 years, with the latest figure at -$520000.0 in Q4 2017.

• For the quarter ending Q4 2017, Deferred Taxes changed N/A year-over-year to -$520000.0; the trailing twelve-month figure through Dec 2017 stood at -$513000.0 (down 8650.0% YoY), and the FY2017 full-year result was -$513000.0, down 8650.0% from the prior year.
• Deferred Taxes for Q4 2017 stood at -$520000.0, down from -$19000.0 in the prior quarter.
• The five-year high for Deferred Taxes was $25000.0 in Q2 2017, with the low at -$520000.0 in Q4 2017.
• Historically, Deferred Taxes has averaged -$72000.0 across 3 years, with a median of $3000.0 in 2015.
• The largest YoY upside for Deferred Taxes was 733.33% in 2017 against a maximum downside of 66.67% in 2017.
• CytomX Therapeutics' Deferred Taxes stood at $3000.0 in 2015, then changed by 0.0% to $3000.0 in 2016, then slumped by 17433.33% to -$520000.0 in 2017.
• The last three Deferred Taxes figures came in at -$520000.0 (Q4 2017), -$19000.0 (Q3 2017), and $25000.0 (Q2 2017), per Business Quant data.